首页> 外文OA文献 >PCN67 LOWER ADMINISTRATION COSTS OF BEVACIZUMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY VERSUS CETUXIMAB-VINORELBINE-CISPLATIN THERAPY FOR THE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER (MNSCLC) FOCUSING ON THREE EUROPEAN HEALTH CARE SYSTEMS

【2h】

PCN67 LOWER ADMINISTRATION COSTS OF BEVACIZUMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY VERSUS CETUXIMAB-VINORELBINE-CISPLATIN THERAPY FOR THE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER (MNSCLC) FOCUSING ON THREE EUROPEAN HEALTH CARE SYSTEMS

机译：PCN67降低的贝伐单抗联合铂类化学疗法与西妥昔单抗-长春贝西汀-西铂治疗相结合的治疗成本，用于治疗三种欧洲系统性疾病的转移性非小细胞肺癌（MNSCLC）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Rosery H; Castro de C; Bischoff H; Heigener D; Vergnenegre A; Chouaid C; Walzer S;
展开▼
作者单位

展开▼
年度 2009
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. THE ASSOCIATION BETWEEN INITIATION OF GUIDELINE RECOMMENDED FIRST-LINE SYSTEMIC THERAPY AND HEALTHCARE COSTS AND UTILIZATION IN A METASTATIC NON-SMALL CELL LUNG CANCER (MNSCLC) POPULATION [J] . Casebeer A. W., Hopson S., Antol Drzayich D., Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2016 ,第7期

机译：指南推荐的一线系统治疗和医疗费用与转移性非小细胞肺癌（MNSCLC）人群的使用之间的关联
2. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive ( 50%) metastatic squamous and non-squamous non-small cell lung cancer in France [J] . Chouaid Christos, Bensimon Lionel, Clay Emilie, Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2019 ,第期

机译：PEMBLOLIZUMAB的成本效益分析与法国PD-L1阳性（＆gt.50％）转移性鳞状和非鳞状非小细胞肺癌的第一线治疗的一线治疗方法分析
3. COST-EFFECTIVENESS ANALYSIS OF AFATINIB VERSUS GEFITINIB AS FIRST LINE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM [J] . Santoni N. B., Melo T. G., Aguirre A. R., Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2017 ,第5期

机译：AFATINIB与GEFITINIB的成本效果分析作为巴西私立医疗系统局部晚期或转移表皮生长因子受体突变阳性非小细胞肺癌患者的第一线治疗
4. Pemetrexed versus docetaxel single agent chemotherapy in chemotherapy-naive elderly patients with advanced non-small cell lung cancer [C] . Hua Xin, Zhenguo Han, Haibo Huang 2011 International Conference on Human Health and Biomedical Engineering . 2011

机译：培美曲塞与多西他赛单药化疗在未接受化疗的老年晚期非小细胞肺癌患者中的作用
5. Predictors of changes in health-related quality of life during chemotherapy in an advanced non-small cell lung cancer patient population [D] . Shallwani, Shirin Mehdi 2010

机译：非小细胞肺癌晚期患者化疗期间健康相关生活质量变化的预测因子
6. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy) bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model. [O] . M Hoyle, L Crathorne, J Peters, -1

机译：一线化疗后西妥昔单抗（单药或联合化疗）贝伐单抗（与非奥沙利铂化疗联合）和帕尼单抗（单药）治疗转移性结直肠癌的临床疗效和成本效益（技术评估编号第150号技术评估书和第118号技术评估书的一部分复审：系统的复审和经济模型。
7. PCN161 REIMBURSEMENT OF ADMINISTRATION COSTS ARE UNAFFECTED BY SINGLE, DOUBLE OR TRIPLE ANTI-CANCER THERAPY COMBINATIONS IN THE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER (MNSCLC) IN FRANCE AND GERMANY [O] . Rosery H, Bischoff HG, Vergnenegre A, 2009

机译：在法国和德国治疗转移性非小细胞肺癌（MNSCLC）时，单，双或三抗癌治疗组合不会影响PCN161的管理费用报销

PCN67 LOWER ADMINISTRATION COSTS OF BEVACIZUMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY VERSUS CETUXIMAB-VINORELBINE-CISPLATIN THERAPY FOR THE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER (MNSCLC) FOCUSING ON THREE EUROPEAN HEALTH CARE SYSTEMS

著录项

相似文献

相关主题

期刊订阅